Skip to content
Southworks Pulse

Giving Pluripotent Cells in Utero to Babies with Spina Bifida Improves Life Outcomes, Study Reveals

An innovative medical trial has discovered that providing pluripotent cells to developing infants suffering from spina bifida as part of a surgical repair can be a "major milestone" in addressing congenital conditions.

Trial Details and Safety

The American study involved six unborn babies with a severe neural tube defect. Doctors administered placenta-derived mesenchymal stem cells on the exposed area of the baby's spinal cord during the repair procedure.

Critically, the regenerative treatment demonstrated a favorable safety profile. Doctors verified that the therapy did not induce neoplasms, interfere with wound healing, or block the correction of co-occurring hindbrain herniation.

Encouraging Results

Magnetic resonance imaging performed on the newborns showed a complete reversal of hindbrain herniation in each of the babies. This favorable anatomical change is a key indicator for better mobility and function.

"If it makes additional babies able to walk who previously could not, then it would become their standard of care," commented the principal investigator. "The results are super exciting and create a pathway toward lots of potential novel therapies."

Broader Impact and Encouragement

Commentators reviewing the findings proposed that further confirmation of these observed advantages could herald a "new era" in prenatal intervention. The possibility of ameliorating nerve function impairment seen in utero is viewed as a transformative goal.

Particularly welcome would be better management of continence and digestive health, which are typical difficulties for people affected by this disorder.

The Path Forward

Despite this being a first-in-human effort involved a limited number of patients, its safety demonstration and positive signals offer a robust platform for broader investigative efforts. The combination of regenerative medicine with current in-utero repair procedures presents significant potential for changing life trajectories for future generations with myelomeningocele.

Written by

Nancy Chase

Elena Rodriguez is a senior technology strategist with over a decade of experience in digital innovation and enterprise solutions.

Southworks Pulse

Type to search articles.